

# STRAGEN NEW DRUG DEVELOPMENT



STRAGEN New Drug Development identifies promising patented compounds from biotechnology start-ups as well as academic institutions and develops these into drugs of high therapeutic potential.

STRAGEN designs and conducts the full development programme, from pre-clinical to manufacturing scale-up, paving the way to global registration.

## ALX-009 Cystic Fibrosis

Developed by the new biotechnology start-up Alaxia in which STRAGEN acquired a significant stake in 2011

• First-in-class orphan drug

• Targets multi-drug-resistant (MDR) bacterial infections not treatable by current antibiotic therapies

• Ready-to-inhale combination of two endogenous substances contributing to the innate immune system response

• Innovative mode of action: Activity unaffected by CF patient's sputum and no emergence of bacterial resistance

2019 Start of Proof of Concept in Cystic Fibrosis (MDR infections)

2018 First in Man clinical trial including Cystic Fibrosis patients

2017 First in Man clinical trial completed in healthy volunteers

2016 The Cystic Fibrosis Foundation supports the ALX-009 development programme scientifically & financially

2015 Start of First-in-Man clinical study for ALX-009 in healthy volunteers and Cystic Fibrosis patients

2013 BPI France supports the ALX-009 development programme

2011 Investment in Alaxia, a French biotech company developing ALX-009

2019 Proof of Concept in neuropathic pain

2018 First-in-Man clinical trials with injectable forms

2017

2016 Completion of preclinical and pharmaceutical development for STR-324

2015 Exclusive worldwide license for STR-324

2013

2011 Pre-development agreement with Institut Pasteur (France) for STR-324

## STR-324 Pain

• First-in-class non-opioid pain killer

• Safe, non-addictive, and innovative mode of action

• Efficiency for acute and prolonged pain, including neuropathic pain (animal models)

• Synthetic equivalent of a natural occurring human pentapeptide

• Inhibits the degradation of enkephalins, endogenous painkillers released only during and at the site of a painful situation

• Absence of respiratory, gastro-intestinal, or central nervous system side effects in animals (in contrast to opioids)